Table 2. Orthogonal test L9 (34) design and result.
Run | Bre (mg) | E80 (mg) | MCT (mg) | ODA (mg) | PDI | Size (nm) |
---|---|---|---|---|---|---|
1 | 8 | 100 | 20 | 4 | 0.236 | 0.236 |
2 | 8 | 120 | 40 | 6 | 0.206 | 0.206 |
3 | 8 | 140 | 60 | 8 | 0.232 | 0.232 |
4 | 10 | 100 | 40 | 8 | 0.268 | 0.268 |
5 | 10 | 120 | 60 | 4 | 0.253 | 0.253 |
6 | 10 | 140 | 20 | 6 | 0.266 | 0.266 |
7 | 12 | 100 | 60 | 6 | 0.221 | 0.221 |
8 | 12 | 120 | 20 | 8 | 0.226 | 0.226 |
9 | 12 | 140 | 40 | 4 | 0.192 | 0.192 |
K1PDI | 0.225 | 0.242 | 0.243 | 0.227 | ||
K2PDI | 0.262 | 0.228 | 0.222 | 0.231 | ||
K3PDI | 0.213 | 0.230 | 0.230 | 0.242 | ||
K1size | 195.200 | 209.700 | 197.600 | 197.767 | ||
K2size | 215.333 | 188.300 | 199.200 | 201.967 | ||
K3size | 192.733 | 205.267 | 206.467 | 203.533 | ||
RPDI | 0.049 | 0.014 | 0.021 | 0.015 | ||
Rsize | 22.600 | 21.400 | 8.867 | 5.766 |
Bre, breviscapine; E80, egg yolk lecithin 80; MCT, medium-chain fatty acid esters; ODA, octadecylamine; PDI, polydispersity index.